Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous tumor cell vaccine (NCI, follicular lymphoma)
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- Vaccines & Immunotherapeutics, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
The autologous tumor cell vaccine developed by the National Cancer Institute (NCI) for follicular lymphoma is an investigational immunotherapy consisting of membrane-patched proteoliposomes. This formulation is created by extracting membrane proteins from a patient's own (autologous) follicular lymphoma cells and incorporating them into liposomes along with interleukin-2 (IL-2/aldesleukin). The vaccine is designed to present a comprehensive profile of patient-specific tumor antigens to the immune system while utilizing IL-2 as a potent adjuvant to stimulate T-cell proliferation and activation. This approach aims to bypass the need for identifying specific idiotype proteins by using the entire tumor membrane proteome. It has been studied in Phase I clinical trials for patients with advanced or recurrent follicular lymphoma to assess safety and the induction of anti-tumor immune responses.
- Other names
- membrane-patched proteoliposomesautologous tumor cell vaccine with IL-2autologous tumor cell vaccine-National Cancer Institute (NCI)-follicular lymphoma
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)
Beyond the preview
Go deeper on autologous tumor cell vaccine (NCI, follicular lymphoma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous tumor cell vaccine (NCI, follicular lymphoma).